Spanish dermatology specialist Almirall (ALM: MC) has agreed to buy an option from California’s Dermira (Nasdaq: DERM) related to the investigational biologic lebrikizumab.
Almirall will pay $30 million for the option to exclusively license rights for the development and commercialization of the candidate, for the treatment of atopic dermatitis and certain other indications, within Europe.
Following the results of the ongoing Phase IIb study, should Almirall exercise its option, Dermira will receive a $50 million fee plus additional development, regulatory and sales milestone payments, as well as double-digit royalties.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze